Cancer Discovery癌症发现
Cancer Discovery(英文缩写 CANCER DISCOV),ISSN 2159-8274,eISSN 2159-8290,中文译名:癌症发现 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 38.272 | Q1 |
| 2022 | 28.200 | Q1 |
| 2023 | 29.700 | Q1 |
| 2024 | 33.300 | Q1 |
| 2025 | 29.500 | Q1 |
Cancer Discovery 最新收录文献
-
1. Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
PMID:日期:2026-09-25Allogeneic CAR T cells could overcome limitations of autologous therapies but are limited by immune rejection. We evaluated 11 patients with large B‑cell lymphoma treated with a single lot of cemacabtagene ansegedleucel (cema-cel), an allogeneic anti‑CD19 CAR T product. Despite receiving identical infusion products, patients exhibited heterogeneous cema-cel expansion and clinical outcomes. Our integrated analyses using longitudinal TCRβ sequencing, single‑cell molecular profiling, and mixed lymphocyte reaction assays revealed that high frequencies of pre‑existing, recipient-derived alloreactive CD8+ T cells mediated rapid CAR T rejection in non-expanders. Furthermore, effector-like features, rather than stem/central memory programs, drove robust clonal CAR T expansion consistently across expanders. We confirmed similar expansion patterns in two independent cohorts treated with a separate lot of cema-cel or an allogeneic anti-BCMA CAR T product. These findings highlight distinct cell‑extrinsic and cell‑intrinsic mechanisms that influence allogeneic CAR T performance and provide insights to optimize donor selection, manufacturing, and product design.
-
2. Microplastics and Cancer: Still Searching for Causation.
PMID:日期:2026-09-24Micro- and nanoplastics have been found in tumors throughout the human body, from the gut and lung to the brain and prostate, and laboratory work ties them to inflammation, DNA damage, and other cancer-related changes. But nearly all that evidence is either associative or drawn from animals and cells. Researchers say a causal verdict will require studies that measure exposure before disease appears, a bar the field has not yet cleared.
-
3. Spatial Immune Reorganization Characterizes Immunosuppressed Skin Tumors.
PMID:日期:2026-09-23该文献暂无摘要。
-
4. Targeting RAS for Pancreatic Cancer Interception.
PMID:日期:2026-09-22Multiple strategies to target RAS are now available to treat pancreatic cancer. As pancreatic precancers also have KRAS mutations, these tools hold great promise for cancer interception.
-
5. The liver niche accelerates, while the lung niche restrains secondary spread of breast cancer.
PMID:日期:2026-09-22Breast cancer progression to visceral organs such as the lung and liver is associated with poor prognosis. Yet, these organs have diverse cellular microenvironments that may differentially influence cancer cell behavior. Here, we show that breast cancer metastases differ in their capacity for secondary seeding: the liver fosters metastasis-promoting properties and boosts secondary spread, whereas the lung restricts these processes, favoring local growth. Using patient data and rapid autopsy tissues, mouse models with barcode-mediated tracing, niche-labeling technology, and single-cell analysis of tumor cells and their direct microenvironment, we dissect the cellular and molecular microenvironmental factors underlying this differential behavior. Mechanistically, we identify BMP2-producing endothelial cells as critical players within the liver metastatic niche, enhancing metastasis-to-metastasis dissemination. Targeting the BMP2 signaling axis suppresses secondary spread of liver-derived breast cancer lesions. Altogether, we reveal site-specific behavior of lung and liver metastases in breast cancer, highlighting microenvironmental mechanisms and therapeutic opportunities for intervention.
-
7. Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.
7. B7-H3-MAPK信号的双重功能通过调控髓源性抑制细胞和成纤维细胞的可塑性协调肿瘤免疫抑制PMID:日期:2026-09-18B7-H3/CD276 is an emerging immunotherapy target in cancers. However, limited knowledge of B7-H3 signaling and its role in modulating the tumor microenvironment hinders the clinical application of B7-H3-targeting therapy. Here, we report that B7-H3 plays dual roles in regulating myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs), thereby promoting tumor progression and therapy resistance, respectively. We comprehensively characterized a non-canonical function of B7-H3 that triggers MAPK signaling in monocytic MDSCs and induces cellular senescence. The senescent monocytic M-MDSCs secreted chemokines to recruit immunosuppressive granulocytic MDSCs. Genetic deletion or pharmacological inhibition of B7-H3/Cd276 reduced Gr-MDSCs and delayed tumor progression. Nevertheless, the secretory factor SPINK1 derived from MDSCs compensatorily activates EGFR/MEK/ERK signaling in CAFs and promotes their extracellular matrix remodeling features, dampening B7-H3-targeting immunotherapy. Combining the B7-H3 monoclonal antibody with the FDA-approved MEK inhibitor trametinib showed durable anti-tumor effects in preclinical models of castration-resistant prostate cancer by fully attenuating immunosuppressive mechanisms.
-
8. Rb Activates Pro-Proliferative Estrogen-Responsive Genes in Breast Cancer.
PMID:日期:2026-09-18该文献暂无摘要。
-
9. Phase III Trials Test First-Line Options in Advanced NSCLC.
PMID:日期:2026-09-18Presented at the 2026 World Conference on Lung Cancer, two phase III trials-PAPILLON and REZILIENT3-established amivantamab and zipalertinib combination therapies as effective first-line strategies for advanced NSCLC with EGFR exon 20 insertions, with significantly improved progression-free survival, although high crossover rates prevented them demonstrating an overall survival benefit. Separately, HARMONi-2 showed that the bispecific antibody ivonescimab improved overall survival versus pembrolizumab in PD-L1-positive NSCLC, supporting its use as standard of care in China while larger global trials continue.
-
10. How a Rare Inherited Lung Cancer Mutation Took Root in Appalachia.
PMID:日期:2026-09-17A rare inherited EGFR mutation took root in Southern Appalachia after being carried to the United States by European settlers in the 1700s. Mapping the distribution of this germline EGFRT790M variant could help clinicians identify people at elevated risk of lung cancer and target them for genetic testing and closer surveillance.